Related Experiment Video

Updated: Jun 13, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Adalimumab in juvenile rheumatoid arthritis/juvenile idiopathic arthritis

Katherine Anne B Marzan1, Andreas Otto Reiff

  • 1Childrens Hospital Los Angeles, 4650 Sunset Boulevard, MS#60, Los Angeles, CA 90027, USA. kmarzan@chla.usc.edu

Expert Review of Clinical Immunology
|May 19, 2010
PubMed

Insights

Early treatment of childhood arthritis with anti-tumor necrosis factor (TNF) agents like adalimumab can improve outcomes. This approach helps reduce inflammation, prevent joint damage, and enhance functional ability in pediatric patients.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Chronic arthritis in childhood, a common rheumatic disease, causes significant disability.
  • Tumor necrosis factor-alpha (TNF-a) plays a key role in pediatric arthritis, driving joint inflammation and destruction.
  • Early, aggressive treatment strategies are crucial for improving outcomes in juvenile arthritis.

Purpose of the Study:

  • To evaluate the role of anti-TNF agents in managing juvenile arthritis.
  • To highlight the potential of adalimumab as a therapeutic option for pediatric rheumatic diseases.

Main Methods:

  • Review of current literature on juvenile arthritis treatment paradigms.
  • Analysis of the mechanism of action for anti-TNF biologics.
  • Assessment of adalimumab's efficacy and safety profile in pediatric patients.

Main Results:

  • Anti-TNF agents, including adalimumab, demonstrate significant efficacy in ameliorating clinical signs and symptoms of juvenile arthritis.
  • These therapies effectively inhibit joint destruction and improve functional disability.
  • Adalimumab is emerging as a valuable biologic response modifier for this condition.

Conclusions:

  • Early and aggressive treatment with disease-modifying antirheumatic drugs and biologic response modifiers is essential for optimal outcomes in juvenile arthritis.
  • Anti-TNF agents represent a major advancement in managing pediatric rheumatic diseases.
  • Adalimumab shows promise as an effective therapy for childhood arthritis, improving patient function and reducing long-term disability.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...